Clinomics Inc. (KOSDAQ: 352770)

Market Cap	28.66B
Revenue (ttm)	9.75B
Net Income (ttm)	-33.21B
Shares Out	38.88M
EPS (ttm)	-973.53
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,297,356
Open	690.00
Previous Close	682.00
Day's Range	685.00 - 886.00
52-Week Range	682.00 - 3,080.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2024

About Clinomics

Clinomics Inc., a biotechnology company, provides genome-based cancer and disease diagnostic solutions. It provides TrioDx RT-PCR COVID-19 Test (FDA EUA), liquid biopsy and precision medicines, health care services, and big data solutions. The company’s liquid biopsy and precision medicines include CD-PRIME, a platform that offers automated protocols for the enrichment of circulating tumor cells (CTCs), cell free DNA, and EV (exosome) derived from cancer tissues; Cancer-PRIME, a cancer gene analysis service for analyzing results related to prec...

• Industry: Medical Laboratories
• Founded: 2011
• Employees: 75
• Stock Exchange: KOSDAQ
• Ticker Symbol: 352770

Financial Performance

In 2023, Clinomics's revenue was 11.41 billion, a decrease of -50.58% compared to the previous year's 23.08 billion. Losses were -42.26 billion, 315.2% more than in 2022.